Literature DB >> 6434592

Role of endogenous prostaglandin E2 in erythropoietin production and dome formation by human renal carcinoma cells in culture.

M Hagiwara, D B McNamara, I L Chen, J W Fisher.   

Abstract

Studies were carried out on the role of endogenous prostaglandin E2 (PGE2) in erythropoietin (Ep) production and dome formation in primary monolayer cultures of a human renal carcinoma from a patient with erythrocytosis that has been serially transplanted into BALB/c athymic nude mice. The metabolism of [14C]arachidonic acid (14C-AA) by cultured renal carcinoma cells, which were plated in 25-cm2 flasks at a density of 2 X 10(4) cells/cm2 and grown for 6, 12 (confluence, 13 X 10(4) cells/cm2), 16, 24, and 30 d in Eagle's minimum essential medium (MEM) supplemented with 10% fetal bovine serum, was examined by using radiometric thin-layer chromatography (TLC). TLC revealed PGE2 to be the major metabolite of 14C-AA produced by the cultured cells throughout the 30 d of cultivation. In addition, the cultured cells at each time period were incubated for 24 h in 5 ml of serum-free Eagle's MEM and the levels of PGE2 and Ep in the incubated media were measured via radioimmunoassay. PGE2 levels in the serum-free media incubated with the cultured cells grown for 6 d were significantly (P less than 0.001) elevated (174 +/- 2.5 pg/ml, n = 5), compared with the unincubated control media (1.5 +/- 0.19 pg/ml, n = 5) and gradually decreased at each time period to 97.6 +/- 4.4 pg/ml (n = 5) at 30 d. On the other hand, the levels of Ep in the incubated media of the cells grown for 6 d were 11.5 +/- 0.52 mU/ml (n = 5) compared with 7.6 +/- 0.62 mU/ml (n = 5) in the control media. However, after the cultured cells became confluent, the levels of Ep in the incubated media showed a marked increase to 222.9 +/- 5.26 mU/ml (n = 5) at 30 d of cultivation. Multicellular hemicysts (domes) developed after the cultured cells reached confluence and their numbers increased with increasing time in confluence in parallel with the increase in Ep. Meclofenamate (MF) (3 X 10(-6)-3 X 10(-5) M), a prostaglandin synthesis inhibitor, produced a significant dose-related decrease in PGE2, Ep, and dome formation without producing a significant effect on cell viability in the 30-d cells. This inhibitory effect of MF on Ep production and dome formation was completely abolished by the addition of 10(-8) M PGE2 to the incubation medium. In conclusion, endogenous PGE2 plays an important role in supporting and/or stimulating Ep production and dome formation in cultured renal carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6434592      PMCID: PMC425292          DOI: 10.1172/JCI111535

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  40 in total

Review 1.  Paraneoplastic erythrocytosis and inappropriate erythropoietin production. A review.

Authors:  E B Thorling
Journal:  Scand J Haematol Suppl       Date:  1972

2.  Ultrastructural pathology of human renal cell tumors.

Authors:  M Tannenbaum
Journal:  Pathol Annu       Date:  1971

3.  The effects of prostaglandin E 1 on erythropoietin production.

Authors:  L G Paulo; R D Wilkerson; B L Roh; W J George; J W Fisher
Journal:  Proc Soc Exp Biol Med       Date:  1973-03

4.  A cell line derived from normal dog kidney (MDCK) exhibiting qualities of papillary adenocarcinoma and of renal tubular epithelium.

Authors:  J Leighton; L W Estes; S Mansukhani; Z Brada
Journal:  Cancer       Date:  1970-11       Impact factor: 6.860

5.  Comparative light and electron microscopic observations of the cytoplasmic matrix in renal carcinomas.

Authors:  J L Ericsson; R Seljelid; S Orrenius
Journal:  Virchows Arch Pathol Anat Physiol Klin Med       Date:  1966-10-10

6.  Stimulation of erythropoiesis in plethoric mice by prostaglandins and its inhibition by antierythropoietin.

Authors:  J C Schooley; L J Mahlmann
Journal:  Proc Soc Exp Biol Med       Date:  1971-11

7.  A method for producing specific antisera with small doses of immunogen.

Authors:  J Vaitukaitis; J B Robbins; E Nieschlag; G T Ross
Journal:  J Clin Endocrinol Metab       Date:  1971-12       Impact factor: 5.958

8.  Erythropoietin levels in patients with renal tumors or cysts.

Authors:  G P Murphy; G M Kenny; E A Mirand
Journal:  Cancer       Date:  1970-07       Impact factor: 6.860

9.  Regulation of acetylcholinesterase in neuroblastoma cells.

Authors:  A Blume; F Gilbert; S Wilson; J Farber; R Rosenberg; M Nirenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1970-10       Impact factor: 11.205

10.  The erythropoiesis-stimulating factors produced by tumors.

Authors:  T A Waldmann; W F Rosse; R L Swarm
Journal:  Ann N Y Acad Sci       Date:  1968-03-29       Impact factor: 5.691

View more
  4 in total

1.  The regulated expression of erythropoietin by two human hepatoma cell lines.

Authors:  M A Goldberg; G A Glass; J M Cunningham; H F Bunn
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

2.  Hypoxia-induced accumulation of erythropoietin mRNA in isolated hepatocytes is inhibited by protein kinase C.

Authors:  K U Eckardt; A Ring; M Maier; B Gess; D Fabbro; A Kurtz
Journal:  Pflugers Arch       Date:  1994-01       Impact factor: 3.657

3.  Erythropoietin Exacerbates Inflammation and Increases the Mortality of Histoplasma capsulatum-Infected Mice.

Authors:  Gisele Aparecida Locachevic; Priscilla Aparecida Tartari Pereira; Adriana Secatto; Caroline Fontanari; Alyne Fávero Galvão; Morgana Kelly Borges Prado; Karina Furlani Zoccal; Tânia Petta; Luiz Alberto Beraldo Moraes; Simone Gusmão Ramos; Fabíola Attie de Castro; Carlos Artério Sorgi; Lúcia Helena Faccioli
Journal:  Mediators Inflamm       Date:  2015-10-11       Impact factor: 4.711

4.  Paraneoplastic Erythrocytosis of Colon Cancer, with Serum Erythropoietin within the Normal Reference Range.

Authors:  Hiromitsu Kitayama; Tomonhiro Kondo; Junko Sugiyama; Michiaki Hirayama; Yumiko Oyamada; Yasushi Tsuji
Journal:  Am J Case Rep       Date:  2016-06-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.